Perspective Therapeutics Inc (CATX)

개요 뉴스 가격 이력 토론 예측 주식 분할

Relative Volume:

Perspective Therapeutics Inc Stock (CATX) Company Profile

Perspective Therapeutics Inc

Healthcare (1111)

Medical Devices (139)

509-375-1202

350 Hills Street, Suite 106, Richland

최신 SEC 제출 서류

CATX's Discussions on Twitter

Compare CATX vs ABT, SYK, MDT, BSX, EW

주식	가격	시가총액	매출	순이익	현금흐름	주당 순 이익
CATX Perspective Therapeutics Inc	4.70	571.85M	6.96M	-46.51M	-37.99M	-0.1716
ABT Abbott Laboratories	112.68	193.83B	44.33B	6.48B	6.92B	3.7033
SYK Stryker Corp	366.05	140.01B	25.12B	3.25B	4.28B	8.3984
MDT Medtronic Plc	99.49	129.33B	34.76B	4.79B	5.21B	3.7017
BSX Boston Scientific Corp	74.73	109.92B	20.08B	2.89B	3.82B	1.9391
EW Edwards Lifesciences Corp	75.87	44.36B	6.07B	1.06B	799.60M	1.8527

Perspective Therapeutics Inc Stock (CATX) Upgrades & Downgrades

날짜	액션	분석자	등급 변경
2025-11-24	재개	Truist	Buy
2025-10-10	개시	BTIG Research	Buy
2025-03-13	개시	H.C. Wainwright	Buy
2025-03-07	개시	Scotiabank	Sector Outperform
2024-11-25	다운그레이드	BofA Securities	Buy → Neutral
2024-10-24	개시	UBS	Buy
2024-10-01	개시	Wedbush	Outperform
2024-09-25	개시	Truist	Buy
2024-07-25	개시	BofA Securities	Buy
2024-05-09	개시	Cantor Fitzgerald	Overweight

Perspective Therapeutics Inc 주식(CATX)의 최신 뉴스

Perspective Therapeutics Inc (CATX) 재무 분석

Perspective Therapeutics Inc (CATX)

Perspective Therapeutics Inc Stock (CATX) Company Profile

Compare CATX vs ABT, SYK, MDT, BSX, EW

Perspective Therapeutics Inc Stock (CATX) Upgrades & Downgrades

Perspective Therapeutics Inc 주식(CATX)의 최신 뉴스

Can Perspective Therapeutics Inc. lead its sector in growthDividend Hike & Low Drawdown Investment Ideas - mfd.ru

Will Perspective Therapeutics Inc. benefit from rising consumer demandJuly 2025 Patterns & Low Risk High Win Rate Stock Picks - mfd.ru

Can Perspective Therapeutics Inc. expand into new marketsLayoff News & Safe Capital Investment Plans - mfd.ru

Activity Recap: Does Perspective Therapeutics Inc stock have upside surprise potentialExit Point & Technical Buy Zone Confirmations - baoquankhu1.vn

Perspective Therapeutics (CATX) Is Up 92.6% After $175M Equity Raise To Fund Targeted Alpha Therapies – Has The Bull Case Changed? - Yahoo Finance

Perspective Therapeutics Raises Capital to Advance Radiopharmaceutical Pipeline - TipRanks

Perspective Therapeutics Prices Approx. $175 Mln Offering Of Shares And Pre-Funded Warrants - Nasdaq

Perspective Therapeutics (CATX) Raises $175 Million Through Stoc - GuruFocus

Perspective Therapeutics shares rise after $175 million offering By Investing.com - Investing.com South Africa

Perspective Therapeutics shares rise after $175 million offering - Investing.com

Perspective Therapeutics jumps after $175 mln equity offering - TradingView

Perspective Therapeutics (CATX) Announces $175M Public Offering - GuruFocus

Perspective Therapeutics prices 39.58M shares at $3.79 in underwritten offering - TipRanks

Perspective Therapeutics prices $175M equity offering; shares up - MSN

Perspective Therapeutics Announces Pricing of $175 Million Underwritten Offering of Common Stock and Pre-Funded Warrants - marketscreener.com

Perspective Therapeutics taps $175M stock sale to fund cancer radiopharma work - Stock Titan

Comparing Perspective Therapeutics (NASDAQ:CATX) & Biosig Technologies (NASDAQ:STEX) - Defense World

Brokerages Set Perspective Therapeutics (NASDAQ:CATX) Target Price at $11.17 - Defense World

A Look At Perspective Therapeutics (CATX) Valuation After New VMT-α-NET Trial And Pipeline Updates - Yahoo Finance

Perspective Therapeutics: VMT-A-NET Presses On In SSTR2-Solid Tumor Targeting Space (CATX) - Seeking Alpha

Perspective Therapeutics (CATX) Rating Maintained, Price Target Raised by HC Wainwright & Co. | CATX Stock News - GuruFocus

Why Perspective Therapeutics (CATX) Is Up 59.6% After New VMT-α-NET Trial Data And Expansion Plans - Sahm

Perspective Therapeutics (NASDAQ:CATX) Given Average Rating of "Buy" by Analysts - MarketBeat

Perspective Therapeutics stock price target raised to $12 from $10 at H.C. Wainwright By Investing.com - Investing.com Canada

Perspective Therapeutics (NASDAQ:CATX) Given Outperform Rating at Wedbush - MarketBeat

CATX: Wedbush Reiterates Outperform Rating with Maintained Price Target | CATX Stock News - GuruFocus

$668B Oncology Surge: 5 Platforms Cracking the Code on GI Tumors - Sahm

What is the next catalyst for Perspective Therapeutics Inc.2025 Fundamental Recap & AI Powered Buy and Sell Recommendations - mfd.ru

Perspective Therapeutics stock price target raised to $12 from $10 at H.C. Wainwright - Investing.com Canada

Perspective Therapeutics stock (CATX) steadies before the open after 66% jump — what investors watch next - TechStock²

Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) Given Average Recommendation of "Buy" by Analysts - MarketBeat

Growth Report: Does Perspective Therapeutics Inc stock have upside surprise potential2025 Investor Takeaways & Short-Term Swing Trade Alerts - baoquankhu1.vn

Perspective Therapeutics (NYSEAMERICAN:CATX) Shares Down 4.4%Time to Sell? - MarketBeat

Can Perspective Therapeutics Inc expand into new marketsQuarterly Trade Review & Precise Buy Zone Identification - baoquankhu1.vn

Signal Recap: Whats the MACD signal for APLSPortfolio Performance Summary & Accurate Intraday Trading Signals - baoquankhu1.vn

Reviewing Perspective Therapeutics (NASDAQ:CATX) & CapsoVision (NASDAQ:CV) - Defense World

Analyzing Carlsmed (NASDAQ:CARL) and Perspective Therapeutics (NASDAQ:CATX) - Defense World

Aug Momentum: Is Perspective Therapeutics Inc part of any major indexRate Hike & Community Supported Trade Ideas - baoquankhu1.vn

CEO Moves: Is Perspective Therapeutics Inc part of any major indexMarket Performance Recap & Weekly Return Optimization Plans - baoquankhu1.vn

Critical Contrast: Perspective Therapeutics (NASDAQ:CATX) and Shoulder Innovations (NYSE:SI) - Defense World

Perspective Therapeutics, Inc Updates Corporate Presentation on Radiopharmaceuticals - TradingView — Track All Markets

Perspective Therapeutics (NASDAQ:CATX) Receives “Buy” Rating from BTIG Research - Defense World

BTIG Reiterates 'Buy' Rating for Perspective Therapeutics (CATX) with $14 PT | CATX Stock News - GuruFocus

Perspective Therapeutics' (CATX) Buy Rating Reiterated at BTIG Research - MarketBeat

Short Covering: Can Perspective Therapeutics Inc generate free cash flowEarnings Overview Summary & Consistent Growth Equity Picks - baoquankhu1.vn

Perspective Therapeutics outlines 2026 clinical and manufacturing priorities - TipRanks

Perspective Therapeutics Provides Business Updates and Strategic Priorities - TradingView

Perspective Therapeutics Provides Business Updates and - GlobeNewswire

How Perspective Therapeutics Inc. stock benefits from global expansionPerformance Line Overview & walk-ready comfort choices - Улправда

Perspective Therapeutics Reports Positive Interim Neuroendocrine Tumor Data - TipRanks

Perspective Therapeutics Presents Updated Interim Data of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial at the 2026 ASCO Gastrointestinal Cancers Symposium - The Manila Times

Perspective Therapeutics Inc (CATX) 재무 분석

매출

순이익

현금흐름

주당 순 이익

CATX과 유사한 종목